Nine-amino acid neuropeptide researched for sleep regulation, stress adaptation, and normalization of disturbed sleep architecture.
Last Updated: May 2026
DSIP (Delta Sleep-Inducing Peptide), also designated Emideltide, is a nine-amino-acid neuropeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood during slow-wave sleep induction. It is researched for sleep regulation, stress adaptation, and normalization of disturbed sleep architecture, with mechanism remaining incompletely characterized despite decades of research. DSIP is not approved by major Western regulators. Important regulatory update: DSIP (Emideltide) was removed from the FDA's Category 2 bulk substances list on April 22, 2026 and is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review in July 2026.
DSIP is a nine-amino-acid neuropeptide first isolated in 1974 from cerebral venous blood of rabbits during electrically-induced slow-wave sleep, named for its ability to induce delta-frequency EEG activity associated with deep sleep. Despite decades of research, the precise molecular mechanism remains incompletely characterized — proposed mechanisms include modulation of multiple neurotransmitter systems (GABA, serotonin), HPA axis effects, and direct EEG-influencing effects through poorly-defined receptor mechanisms. Endogenous DSIP-like activity has been documented in human plasma. Evidence level: Preclinical extensive (sleep architecture, stress effects); limited human clinical research; mechanism incompletely characterized.
Preclinical and limited human research has explored DSIP for sleep architecture normalization in insomnia, stress adaptation, and alcohol withdrawal contexts. Effects on sleep latency, sleep efficiency, and slow-wave sleep duration have been reported with varied magnitude across studies. The compound has not advanced to formal Phase 2/3 pharmaceutical development by any sponsor; the research base is academic and exploratory rather than industry-sponsored. Evidence level: Preclinical (multiple sleep models); limited human research; no formal Phase 2/3 development.
DSIP occupies a distinct niche in sleep-research compounds — endogenous origin, neuropeptide structure, focus on sleep architecture rather than direct sedation. Unlike sedative-hypnotics or melatonin-pathway compounds, DSIP's proposed mechanism is sleep-architecture normalization rather than sleep induction.
| Sleep-related compound | Class | Primary effect | Evidence stage |
|---|---|---|---|
| DSIP | Endogenous neuropeptide | Sleep architecture normalization | Preclinical + limited human |
| Benzodiazepines | GABA-A agonist | Sedation, sleep induction | FDA-approved |
| Melatonin | Pineal hormone | Circadian phase shift | OTC supplement |
| Z-drugs (zolpidem) | GABA-A subtype agonist | Sleep induction | FDA-approved |
Side effects in available research use are generally mild — occasional mild stimulation effects (paradoxical given the sleep-related mechanism), transient headache, and injection-site reactions. The endogenous origin and limited systemic effects support a favorable inherent safety profile. Long-term safety in humans at sustained research-use dosing is not characterized at Western RCT standards. Evidence level: Preclinical safety; limited human safety; long-term unestablished.
DSIP (also Emideltide) is not approved for any medical indication anywhere in the world as of May 2026. On April 22, 2026, DSIP/Emideltide was removed from the FDA's Category 2 bulk substances list and is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review in July 2026. Removal from Category 2 does not authorize compounding — formal Category 1 inclusion or 503A bulks list addition remains pending PCAC determination. Current status in FDA peptide regulation 2025–2026 timeline.
DSIP synthesis is mature and broadly available, but the nine-amino-acid sequence shares amino acid composition patterns with related neuropeptides — mass spectrometry identity confirmation is important. The compound is relatively niche, with fewer vendors and varied quality control across the available market. Independent HPLC purity testing and mass spectrometry are the standard quality signals. Guidance in how-to-test-peptides hub.
Peptigrity purchases DSIP vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.
DSIP is researched for sleep architecture normalization — particularly increasing slow-wave (delta) sleep — and for stress adaptation effects. The precise mechanism remains incompletely characterized despite decades of research. Human clinical evidence is more limited than the preclinical base.
DSIP (Emideltide) is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. The April 22, 2026 Category 2 removal opens a potential future compounding pathway pending PCAC review in July 2026. Country breakdown in peptide legal status guide.
DSIP (Emideltide) is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review in July 2026. Track developments in FDA peptide regulation 2025–2026 timeline.
DSIP's proposed mechanism is sleep architecture normalization through poorly-characterized neuropeptide pathways — different from melatonin (circadian rhythm signaling) or GABA-A-targeted sleep medications (direct sedation). None of these are mechanistically interchangeable.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. COA interpretation in red flags in peptide certificates of analysis.
No. DSIP is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies. Anyone considering use should consult a licensed physician — particularly for sleep concerns where evidence-based options exist.
This section is for educational and informational purposes only and does not constitute medical advice. DSIP (Emideltide) is not approved by the FDA or any major Western regulator for human use, though it was removed from Category 2 of the FDA 503A bulk substances list in April 2026 and is scheduled for PCAC review in July 2026. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.